AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05295810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Gas Delivery
Description: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)
Study NCT05664672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN Product 1
Description: Mint on!® 2 mg nicotine pouches
Study NCT05664672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN Product 2
Description: Mint on!® 4 mg nicotine pouches
Study NCT04935333 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of Leiomyoma samples
Description: Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.
Study NCT04935333 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of Leiomyosarcoma samples
Description: Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.
Study NCT04935333 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of control samples
Description: Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
Study NCT06109155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
Study NCT06109155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
Study NCT05664672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN Product 3
Description: Mint on!® 8 mg nicotine pouches
Study NCT05664672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Tobacco
Description: subjects completely stop all tobacco product usage for 7 days
Study NCT06562192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NNS309
Description: Radioligand imaging agent
Study NCT06562192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-NNS309
Description: Radioligand therapy
Study NCT06013579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 Gym Exercise HIIT
Description: Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
Study NCT06013579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 Gym Exercise CME
Description: Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
Study NCT06013579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Home Exercise Coaching Text Messages
Description: The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
Study NCT06013579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2 Home Exercise Control Text Messages
Description: The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group.
Study NCT04671589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Administration Intravenous meropenem 1gram every 8 hours together with standard care;~.
Study NCT04671589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem Injection
Description: Administration Intravenous meropenem 1gram every 8 hours together with standard care;~.
Study NCT06392009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil
Description: Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
Study NCT06019793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS for Chronic Pain
Description: Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
Study NCT05674461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WhatsApp Group
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR Trainings will be sent to the women in the WhatsApp experimental group in the form of videos via the WhatsApp application. The videos will be prepared with the researchers' own voice and image. Each training video will be sent for 15-30 minutes (in the form of short videos, if necessary, divided into parts). At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
Study NCT05674461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face Group
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR The trainings will be given to the women in the experimental group face-to-face by the researchers in the form of 15-30 minutes of training in their own home environment. At the end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
Study NCT05674461 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Each of the women will be informed about the purpose and content of the study at the first meeting, and informed consent will be obtained from the women who meet the conditions for participation and agree to participate. The pre-test data in the research will be obtained with the Participant Identification Form and WHOQOL-BREF-TR No intervention will be applied to the mothers in the control group. The end of the 2nd and 6th months, the final test data will be obtained by completing the Participant Identification Form and WHOQOL-BREF-TR
Study NCT05169567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT05169567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM.
Study NCT05169567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Administered IM.
Study NCT05169567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT06502821 — intervention group
Intervention type: OTHER
Intervention: questtionnaire
Description: questionnaire regarding workplace preferences and the factors influencing choosing a career in physiotherapy
Study NCT01687127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Supplement
Study NCT01687127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate, calcium salt
Description: Supplement
Study NCT05206305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation device
Description: Cognito Therapeutics GammaSense Stimulation device delivers sensory (auditory and visual) stimuli at a rate of 40 Hz to the wearer for one hour each day.
Study NCT04920786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: TB006
Study NCT04920786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline (Placebo)
Description: Sterile saline
Study NCT06427577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZhenQi FuZheng granules (ShiDaiYangGuang)
Description: 1 bag at a time, twice a day. Oral orally for 4 weeks.
Study NCT05653388 — intervention group
Intervention type: OTHER
Intervention: Plasma Collection
Description: Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
Study NCT04928508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK-1
Description: OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg
Study NCT04784806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground beef
Description: Subjects will consume a 106g patty of cooked ground beef.
Study NCT04784806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground pork
Description: Subjects will consume a 118g patty of cooked ground pork
Study NCT04784806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: Subjects will consume a 113g patty of cooked tofu
Study NCT04784806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beyond Meat
Description: Subjects will consume a 113g BeyondMeat patty.
Study NCT05039944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: In Arm_A, B and C, the intravenous infusion dose of SI-B001 was single drug RP2D selected in phase I (Q2W); In Cohort_D, E, and F, SI-B001 was divided into two doses, the high dose was the single drug RP2D selected in phase I clinical trial, and the low dose was the second low dose of single drug RP2D, both of which were administered by intravenous infusion.
Study NCT05629715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROSA Knee System
Description: The Zimmer Biomet ROSA Knee System is a commercially available, FDA approved robotic assistant for performing TKA. It uses preoperative x-rays to create a three-dimensional image of the patient's knee anatomy which is used to create a preoperative template of the implants to be used and provides intraoperative guidance for bone cuts during the TKA. The robotic system also assesses the soft tissue envelope around the knee and can assist with the soft tissue balancing of the knee arthroplasty. Alternatively, it can also be used in an imageless mode where bone cuts are performed based on intra-operative mapping using anatomic landmarks.
Study NCT06452485 — intervention group
Intervention type: OTHER
Intervention: No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.
Description: Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
Study NCT05629715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KneeAlign Computer Assisted Navigation System
Description: The OrthAlign KneeAlign computer assisted navigation system is a commercially available device that uses gyroscopic limb position sensing technology mounted to intramedullary and extramedullary jigs to measure bone resection cuts in TKA that ultimately dictate implant position.
Study NCT06343844 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiac imaging to assess left ventricular volumes and function
Description: non-invasive cardiac imaging (echocardiography and MRI)
Study NCT05366439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-752
Description: Parallel Assignment
Study NCT05366439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Parallel Assignment
Study NCT05039944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administration by intravenous infusion, 180 mg/m2 Q2W.
Study NCT05039944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
Study NCT05039944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX Protocol
Description: FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
Study NCT05893381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA I&T
Description: The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
Study NCT05893381 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiotherapy
Description: Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
Study NCT05893381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy
Description: Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
Study NCT04049539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT06341816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VEXUS score
Description: The VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
Study NCT05502406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft tissue Mobilization
Description: Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
Study NCT06341816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NGAL
Description: Neutrophil gelatinase-associated lipocalin
Study NCT05439681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400
Description: medium cut off (MCO) membrane
Study NCT05439681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX 10
Description: low-flux membrane
Study NCT05439681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX CorDiax 800
Description: high-flux membrane
Study NCT05439681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDF
Description: hemodiafiltration
Study NCT04970615 — intervention group
Intervention type: DEVICE
Intervention: Three-dimensional printed model
Description: Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
Study NCT05469672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.
Study NCT05469672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity laser therapy
Description: HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.
Study NCT04632225 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engensis
Description: Lyophilized biologic to be reconstituted containing Engensis
Study NCT04632225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable liquid
Study NCT05502406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Myofascial Release
Description: Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand
Study NCT04945291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: New way of counting calories using the hands
Description: The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
Study NCT04945291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New way of counting calories using the hands
Description: The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
Study NCT04945291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile applications
Description: the participant will use a mobile application to log their calories
Study NCT05717569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
Study NCT05334030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Swing Assistance
Description: On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting
Study NCT05334030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neutral Swing Assistance
Description: On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting